Ketamine is an NMDA receptor antagonist, which means it affects the way certain neurotransmitters interact in the brain. By blocking NMDA receptors, ketamine increases the availability of a neurotransmitter called glutamate. This leads to the release of other molecules that promote neural plasticity, the brain’s ability to adapt and change. This process is thought to play a crucial role in reversing the effects of chronic stress and depression.
Ketamine is believed to stimulate the growth of new synapses (connections between neurons) in the brain, a process known as synaptogenesis. This synaptic rewiring is thought to contribute to improved communication between brain cells and may help in restoring healthy brain function, leading to a reduction in depressive symptoms.
There is growing evidence that depression is associated with inflammation in the body and brain. Ketamine has been shown to have anti-inflammatory effects, which could contribute to its antidepressant properties. By reducing inflammation, ketamine may help normalize brain function and alleviate depressive symptoms.
Ketamine’s impact on glutamate, the brain’s primary excitatory neurotransmitter, also affects the balance of another neurotransmitter called GABA (gamma-aminobutyric acid), which has inhibitory effects. This balance between glutamate and GABA is crucial for maintaining stable mood and preventing excessive neural activity associated with depression.
Ketamine has been shown to increase the release of brain-derived neurotrophic factor (BDNF), a protein that supports the growth, maintenance, and survival of neurons. Low levels of BDNF have been linked to depression, and ketamine’s ability to boost BDNF production may contribute to its antidepressant effects.
